← 產業報告目錄

Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region – Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-04-01頁數 297報告編號 MD4755

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global prefilled syringes market is projected to reach USD 14.53 billion by 2031 from USD 8.65 billion in 2026, at a CAGR of 10.9% during the forecast period. “The increasing prevalence of chronic diseases, growing adoption of biologics and biosimilars, rising demand for self-administration, and advancements in biotechnology and pharmaceuticals contribute significantly to the growth of the prefilled syringes market.” The prefilled syringes market has had strong growth due to a number of factors such as the rising incidence of chronic diseases like diabetes, rheumatoid arthritis, and cardiovascular disorders. Moreover, prefilled syringes make it easier to administer medications precisely and consistently to patients with chronic conditions, by providing ready-to-use doses that improve patient compliance and lower the possibility of dosage errors. Additionally, the growing trend of self-administration has also played a major role in the market's growth. Prefilled syringes are preferred by patients due to their comfort and ease of use, as they eliminate the need for dose measurement, hence improving safety and lowering the danger of contamination. “By type, the conventional prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.” Based on type, the conventional prefilled syringes segment is expected to dominate the prefilled syringes market due to several factors. Their ready-to-use nature and pre-measured doses enhance convenience and safety by reducing preparation time and dosing errors. They lower contamination risks and needlestick injuries through advanced safety features. Prefilled syringes improve patient compliance, particularly for chronic conditions, by being user-friendly and encouraging adherence to treatment regimens. Their versatility in therapeutic applications, especially for biologics and chronic disease treatments, coupled with the growing prevalence of such conditions, further drive their market dominance. “By material, the glass prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.” Based on material, the glass prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market. Their superior chemical inertness ensures drug stability and reduces the risk of interactions between the drug and the container, making them ideal for a wide range of pharmaceutical applications. Additionally, glass syringes offer high visibility, allowing for easy inspection of the drug for particulates and discoloration, which is critical for quality control and patient safety. As a result, pharmaceutical companies and healthcare providers prefer glass prefilled syringes for their reliability, safety, and efficiency in drug delivery. “By design, the single-chamber prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.” Based on design, the single-chamber prefilled syringes segment accounted for the largest market share of the prefilled syringes market due to their convenience, safety, and efficiency in drug administration. These syringes, which come pre-loaded with a single dose of medication, minimize the risk of dosing errors and contamination, enhancing patient safety. They streamline the injection process, making it quicker and easier for healthcare providers and patients, thereby improving compliance and treatment outcomes. Moreover, their widespread adoption in various therapeutic areas, particularly in chronic disease management and emergency care, further drives growth in the market. “By application, the cancer segment is expected to hold the largest market share in the prefilled syringes market.” By application, the cancer segment is expected to hold the largest market share due to the increasing prevalence of cancer globally and the rising need for advanced drug delivery systems. Prefilled syringes offer significant advantages for cancer treatment, including precise dosing, reduced risk of contamination, and enhanced patient safety and compliance. As cancer treatments often involve complex medication regimens requiring regular and accurate administration, the convenience and reliability of prefilled syringes become critical. Additionally, advancements in biologics and targeted therapies, which are frequently used in oncology, further drive the demand for prefilled syringes, making the cancer segment the dominant application area in this market. “By region, North America is expected to hold the largest market share in the prefilled syringes market.” North America is expected to hold the largest share of the prefilled syringes market during the forecast period due to several factors. These include a well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and a significant focus on patient safety and convenience. Moreover, the region benefits from robust regulatory frameworks that encourage the adoption of prefilled syringes by ensuring stringent quality standards and safety measures. Additionally, the increasing incidence of chronic diseases requiring regular injections, coupled with rising healthcare expenditures, contribute to the growing demand for prefilled syringes in North America. The presence of major pharmaceutical companies and biotechnology firms further enhances market growth through extensive research and development activities aimed at improving drug delivery systems. A breakdown of the primary participants (supply side) for the prefilled syringes market referred to for this report is provided below: • By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%) • By Designation: C-level Executives (20%), Directors (35%), and Others (45%) • By Region: North America (37%), Europe (34%), Asia Pacific (22%), Latin America (5%), Middle East & Africa (2%) Prominent players in the prefilled syringes market are BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US), Nipro (Japan), Baxter (US), Owen Mumford Ltd. (UK), Weigao Medical International Co., Ltd. (China), Credence MedSystems, Inc. (US), Novartis AG (Switzerland), Stevanato Group (Italy), Polymed (India), MedXL (Canada), Sharps Technology, Inc. (US), Fresenius Kabi (US), DBM S.R.L. (Italy), Taisei Kako Co., Ltd. (Japan), Shandong Province Medicinal Glass Co., Ltd. (China), SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD. (Japan), J.O. PHARMA CO., LTD. (Japan), BMIKOREA (Korea), B. Braun SE ( Germany), and Al Shifa Medical Products Co. (Saudi Arabia). Research Coverage: The report analyzes the prefilled syringes market and aims at estimating the market size and future growth potential of this market based on various segments such as type, material, design, application, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies. Reasons to Buy the Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall prefilled syringes market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers:  Analysis of key drivers (increasing chronic diseases, increasing biologics and biosimilars, and technological advancements), restraints (product recalls and stringent government regulations), opportunities (increasing preference for self-administration of injectables and increasing regulatory support), and challenges (presence of alternative drug delivery methods and infections associated with needlestick injuries) • Market Penetration: It includes extensive information on products offered by the major players in the global prefilled syringes market. The report includes various segments in type, material, design, application, and region. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global prefilled syringes market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by type, material, design, application, and region. • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the prefilled syringes market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global prefilled syringes market.
目錄 Table of Contents
1 INTRODUCTION 27 1.1 STUDY OBJECTIVES 27 1.2 MARKET DEFINITION 27 1.3 STUDY SCOPE 28 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 28 1.3.2 INCLUSIONS & EXCLUSIONS 29 1.3.3 YEARS CONSIDERED 29 1.3.4 CURRENCY CONSIDERED 30 1.4 STAKEHOLDERS 30 1.5 SUMMARY OF CHANGES 31 2 EXECUTIVE SUMMARY 32 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 32 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS 34 2.3 DISRUPTIVE TRENDS SHAPING PREFILLED SYRINGES MARKET 34 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 35 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 36 3 PREMIUM INSIGHTS 37 3.1 PREFILLED SYRINGES MARKET OVERVIEW 37 3.2 PREFILLED SYRINGES MARKET, BY REGION, 2025 VS. 2030 38 3.3 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE AND COUNTRY 39 3.4 PREFILLED SYRINGES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 40 3.5 PREFILLED SYRINGES MARKET: DEVELOPED VS. EMERGING MARKETS 41 4 MARKET OVERVIEW 42 4.1 INTRODUCTION 42 4.2 MARKET DYNAMICS 42 4.2.1 DRIVERS 43 4.2.1.1 Increasing prevalence of chronic diseases 43 4.2.1.2 Growing adoption of self-injection devices 43 4.2.1.3 Increasing adoption of prefilled syringes in parenteral dosage forms 44 4.2.1.4 Increased use of biologics and vaccines 45 4.2.1.5 Technological advancements in prefilled syringes 45 4.2.2 RESTRAINTS 46 4.2.2.1 Stringent government regulations 46 4.2.2.2 Impact of product recalls 46   4.2.3 OPPORTUNITIES 47 4.2.3.1 Growing preference for unit-dose medication using prefilled syringes 47 4.2.3.2 Emerging markets with growing healthcare infrastructure 47 4.2.4 CHALLENGES 48 4.2.4.1 Alternative drug delivery methods 48 4.2.4.2 Infections associated with needlestick injuries 49 4.3 UNMET NEEDS & WHITE SPACES 49 4.3.1 UNMET NEEDS 49 4.3.2 WHITE SPACE OPPORTUNITIES 50 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50 4.4.1 INTERCONNECTED MARKETS 50 4.4.2 CROSS-SECTOR OPPORTUNITIES 50 4.5 STRATEGIC MOVES BY TIER- 1/2/3 PLAYERS 51 5 INDUSTRY TRENDS 52 5.1 PORTER’S FIVE FORCES ANALYSIS 52 5.1.1 THREAT OF NEW ENTRANTS 53 5.1.2 THREAT OF SUBSTITUTES 53 5.1.3 BARGAINING POWER OF SUPPLIERS 53 5.1.4 BARGAINING POWER OF BUYERS 53 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 53 5.2 MACROECONOMIC OUTLOOK 54 5.2.1 GDP TRENDS AND FORECAST 54 5.2.2 TRENDS IN PREFILLED SYRINGES MARKET 56 5.3 VALUE CHAIN ANALYSIS 56 5.4 ECOSYSTEM ANALYSIS 57 5.5 SUPPLY CHAIN ANALYSIS 58 5.6 PRICING ANALYSIS 60 5.6.1 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE, 2022–2025 60 5.6.2 AVERAGE SELLING PRICE TREND OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025 60 5.6.3 AVERAGE SELLING PRICE TREND OF SAFETY PREFILLED SYRINGES, BY REGION, 2022–2025 61 5.6.4 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025 61 5.7 TRADE ANALYSIS 62 5.7.1 IMPORT DATA FOR HS CODE 901831 62 5.7.2 EXPORT DATA FOR HS CODE 901831 62 5.8 KEY CONFERENCES & EVENTS, 2026 63 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 64 5.10 INVESTMENT & FUNDING SCENARIO 65   5.11 CASE STUDY ANALYSIS 65 5.11.1 ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS 65 5.11.2 DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION 66 5.12 IMPACT OF 2025 US TARIFF ON PREFILLED SYRINGES MARKET 67 5.12.1 INTRODUCTION 67 5.12.2 KEY TARIFF RATES 68 5.12.3 PRICE IMPACT ANALYSIS 69 5.12.3.1 Impact on country/region 69 5.12.3.1.1 US 69 5.12.3.1.2 Europe 69 5.12.3.1.3 Asia Pacific 69 5.12.4 IMPACT ON END-USE INDUSTRIES 70 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 71 6.1 KEY EMERGING TECHNOLOGIES 71 6.1.1 KEY TECHNOLOGIES 71 6.1.1.1 Integration Disinfection Unit (IDU) 71 6.1.2 COMPLEMENTARY TECHNOLOGIES 71 6.1.2.1 Cyclic Olefin Polymers (COP) and Cyclic Olefin Copolymers (COC) 71 6.1.3 ADJACENT TECHNOLOGIES 72 6.1.3.1 Integration with autoinjectors 72 6.2 TECHNOLOGY/PRODUCT ROADMAP 72 6.2.1 SHORT-TERM |RECENT TECHNOLOGIES| FOUNDATION & EARLY COMMERCIALIZATION 72 6.2.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 73 6.2.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 74 6.3 PATENT ANALYSIS 75 6.3.1 PATENT PUBLICATION TRENDS FOR PREFILLED SYRINGES 75 6.3.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 75 6.3.3 LIST OF PATENTS 77 6.4 IMPACT OF AI/GEN AI ON PREFILLED SYRINGES MARKET 78 6.4.1 TOP USE CASES AND MARKET POTENTIAL 79 6.4.2 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 79 6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREFILLED SYRINGES MARKET 80 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 80 6.5.1 STEVANATO GROUP: AI-DRIVEN VISUAL INSPECTION FOR PREFILLED SYRINGES 80 6.5.2 SCHOTT PHARMA: AI-ENABLED SMART GLASS & DEFECT PREDICTION 81 6.5.3 GERRESHEIMER: PREDICTIVE QUALITY CONTROL IN FILL-FINISH OPERATIONS 81 7 REGULATORY LANDSCAPE 82 7.1 REGIONAL REGULATIONS AND COMPLIANCE 82 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 7.1.2 INDUSTRY STANDARDS 84 7.2 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 85 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 86 8.1 DECISION-MAKING PROCESS 86 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 86 8.2.1 BUYING CRITERIA 87 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 87 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 88 9 PREFILLED SYRINGES MARKET, BY TYPE 89 9.1 INTRODUCTION 90 9.2 CONVENTIONAL PREFILLED SYRINGES 90 9.2.1 DISPOSABLE PREFILLED SYRINGES 93 9.2.1.1 Increasing focus on patient safety to drive market 93 9.2.2 REUSABLE PREFILLED SYRINGES 95 9.2.2.1 Cost-effectiveness and technological advancements to drive market 95 9.3 SAFETY PREFILLED SYRINGES 97 9.3.1 INTEGRATED SAFETY FEATURES TO BOOST ADOPTION 97 10 PREFILLED SYRINGES MARKET, BY DESIGN 99 10.1 INTRODUCTION 100 10.2 SINGLE-CHAMBER PREFILLED SYRINGES 100 10.2.1 CONVENIENCE, SAFETY, AND EFFICIENCY OF SINGLE-CHAMBER SYRINGES TO SUPPORT MARKET GROWTH 100 10.3 DUAL-CHAMBER PREFILLED SYRINGES 102 10.3.1 ABILITY TO MAINTAIN STABILITY, MINIMIZE DOSING ERRORS, AND MEET REGULATORY STANDARDS TO PROPEL MARKET GROWTH 102 10.4 CUSTOMIZED PREFILLED SYRINGES 104 10.4.1 EASY-TO-READ DOSAGE INDICATORS AND SAFETY MECHANISMS TO BOOST ADOPTION 104 11 PREFILLED SYRINGES MARKET, BY MATERIAL 106 11.1 INTRODUCTION 107 11.2 GLASS PREFILLED SYRINGES 107 11.2.1 ABILITY OF GLASS PREFILLED SYRINGES TO OFFER SUPERIOR BARRIER PROPERTIES TO BOOST MARKET GROWTH 107 11.3 PLASTIC PREFILLED SYRINGES 109 11.3.1 IMPROVED SAFETY, COST-EFFECTIVENESS, VERSATILITY, AND CONVENIENCE TO SUPPORT ADOPTION 109 12 PREFILLED SYRINGES MARKET, BY APPLICATION 111 12.1 INTRODUCTION 112 12.2 DIABETES 112 12.2.1 INCREASING PREVALENCE OF DIABETES TO FAVOR MARKET GROWTH 112 12.3 RHEUMATOID ARTHRITIS 114 12.3.1 RISING DEMAND FOR EFFECTIVE AND CONVENIENT TREATMENT OPTIONS TO AID MARKET GROWTH 114 12.4 ANAPHYLAXIS 116 12.4.1 CONVENIENCE OF PREFILLED SYRINGES TO ADMINISTER MEDICATION QUICKLY TO BOOST ADOPTION 116 12.5 CANCER 118 12.5.1 RISING GLOBAL CANCER RATES TO SPUR MARKET GROWTH 118 12.6 THROMBOSIS 120 12.6.1 MINIMIZED RISK OF CONTAMINATION AND INFECTION ASSOCIATED WITH PREFILLED SYRINGES TO AUGMENT MARKET DEMAND 120 12.7 OPHTHALMOLOGY 121 12.7.1 FEWER SIDE EFFECTS ASSOCIATED WITH PREFILLED SYRINGES COMPARED TO TOPICAL MEDICATIONS TO SUPPORT GROWTH 121 12.8 OTHER APPLICATIONS 123 13 PREFILLED SYRINGES MARKET, BY REGION 124 13.1 INTRODUCTION 125 13.2 NORTH AMERICA 126 13.2.1 US 130 13.2.1.1 US to dominate North American prefilled syringes market during forecast period 130 13.2.2 CANADA 132 13.2.2.1 Rising incidence of chronic diseases to propel market growth 132 13.3 EUROPE 135 13.3.1 GERMANY 138 13.3.1.1 High investment in healthcare R&D to foster innovation in drug delivery technologies 138 13.3.2 UK 140 13.3.2.1 Rising number of patients with cardiovascular diseases and diabetes patients to fuel market growth 140 13.3.3 FRANCE 143 13.3.3.1 Increasing incidence of needlestick injuries and growing trend of self-administration to drive market growth 143 13.3.4 SPAIN 145 13.3.4.1 Increase in biologics production to support market growth 145 13.3.5 ITALY 148 13.3.5.1 Growing focus of pharmaceutical and medical device companies on high-quality manufacturing standards to drive market 148 13.3.6 REST OF EUROPE 150 13.4 ASIA PACIFIC 152 13.4.1 JAPAN 156 13.4.1.1 Increase in geriatric population to augment market growth 156 13.4.2 CHINA 158 13.4.2.1 Large diabetic population to attract pharmaceutical and drug delivery device manufacturers to Chinese market 158 13.4.3 INDIA 161 13.4.3.1 High number of cancer and diabetes cases to fuel market growth 161 13.4.4 AUSTRALIA 163 13.4.4.1 Growing healthcare expenditure and rising focus on chronic disease management to aid market growth 163 13.4.5 SOUTH KOREA 166 13.4.5.1 Well-developed healthcare sector and presence of major pharmaceutical manufacturers to drive market 166 13.4.6 REST OF ASIA PACIFIC 168 13.5 LATIN AMERICA 170 13.5.1 BRAZIL 173 13.5.1.1 Increasing prevalence of obesity and rising use of generic medicines to aid market growth 173 13.5.2 MEXICO 176 13.5.2.1 Rising Healthcare Investment and Pharmaceutical Expansion to propel market growth 176 13.5.3 ARGENTINA 178 13.5.3.1 Increasing geriatric population with chronic diseases to fuel demand for prefilled syringes 178 13.5.4 REST OF LATIN AMERICA 181 13.6 MIDDLE EAST & AFRICA 183 13.6.1 RISING CHRONIC DISEASE BURDEN AND HEALTHCARE INVESTMENTS TO BOOST MARKET 183 13.7 GCC COUNTRIES 186 13.7.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET 186 14 COMPETITIVE LANDSCAPE 189 14.1 INTRODUCTION 189 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 189 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN PREFILLED SYRINGES MARKET 190 14.3 REVENUE ANALYSIS, 2020–2024 191 14.4 MARKET SHARE ANALYSIS, 2025 192 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 194 14.5.1 STARS 194 14.5.2 EMERGING LEADERS 194 14.5.3 PERVASIVE PLAYERS 194 14.5.4 PARTICIPANTS 194 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 196 14.5.5.1 Company footprint 196 14.5.5.2 Region footprint 197 14.5.5.3 Type footprint 198 14.5.5.4 Material footprint 199 14.5.5.5 Design footprint 200 14.5.5.6 Application footprint 201 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 202 14.6.1 PROGRESSIVE COMPANIES 202 14.6.2 RESPONSIVE COMPANIES 202 14.6.3 DYNAMIC COMPANIES 203 14.6.4 STARTING BLOCKS 203 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 204 14.6.5.1 Detailed list of key Startups/SMEs 204 14.6.5.2 Competitive benchmarking of Startups/SMEs 204 14.7 BRAND/PRODUCT COMPARISON 205 14.8 COMPANY VALUATION & FINANCIAL METRICS 206 14.8.1 FINANCIAL METRICS 206 14.8.2 COMPANY VALUATION 206 14.9 R&D EXPENDITURE 207 14.10 COMPETITIVE SCENARIO 207 14.10.1 PRODUCT LAUNCHES AND APPROVALS 207 14.10.2 DEALS 209 14.10.3 EXPANSIONS 210 15 COMPANY PROFILES 212 15.1 KEY PLAYERS 212 15.1.1 BECTON, DICKINSON AND COMPANY (BD) 212 15.1.1.1 Business overview 212 15.1.1.2 Products offered 213 15.1.1.3 Recent developments 215 15.1.1.3.1 Product launches 215 15.1.1.3.2 Deals 215 15.1.1.3.3 Expansions 217 15.1.1.4 MnM view 217 15.1.1.4.1 Right to win 217 15.1.1.4.2 Strategic choices 217 15.1.1.4.3 Weaknesses & competitive threats 218   15.1.2 GERRESHEIMER AG 219 15.1.2.1 Business overview 219 15.1.2.2 Products offered 220 15.1.2.3 Recent developments 221 15.1.2.3.1 Product launches 221 15.1.2.3.2 Deals 221 15.1.2.3.3 Expansions 222 15.1.2.4 MnM view 224 15.1.2.4.1 Right to win 224 15.1.2.4.2 Strategic choices 224 15.1.2.4.3 Weaknesses & competitive threats 224 15.1.3 SCHOTT 225 15.1.3.1 Business overview 225 15.1.3.2 Products offered 226 15.1.3.3 Recent developments 227 15.1.3.3.1 Product launches 227 15.1.3.3.2 Expansions 227 15.1.3.4 MnM view 228 15.1.3.4.1 Right to win 228 15.1.3.4.2 Strategic choices 228 15.1.3.4.3 Weaknesses & competitive threats 228 15.1.4 WEST PHARMACEUTICAL SERVICES, INC. 229 15.1.4.1 Business overview 229 15.1.4.2 Products offered 230 15.1.4.3 Recent developments 231 15.1.4.3.1 Product launches 231 15.1.4.3.2 Deals 231 15.1.4.3.3 Expansions 232 15.1.4.4 MnM view 234 15.1.4.4.1 Right to win 234 15.1.4.4.2 Strategic choices 234 15.1.4.4.3 Weaknesses & competitive threats 234 15.1.5 APTARGROUP, INC. 235 15.1.5.1 Business overview 235 15.1.5.2 Products offered 236 15.1.5.3 Recent developments 237 15.1.5.3.1 Deals 237 15.1.5.3.2 Expansions 237 15.1.5.4 MnM view 238 15.1.5.4.1 Right to win 238 15.1.5.4.2 Strategic choices 238 15.1.5.4.3 Weaknesses & competitive threats 238 15.1.6 NIPRO 239 15.1.6.1 Business overview 239 15.1.6.2 Products offered 240 15.1.6.3 Recent developments 241 15.1.6.3.1 Product launches 241 15.1.6.3.2 Expansions 242 15.1.7 BAXTER (SIMTRA BIOPHARMA SOLUTIONS) 243 15.1.7.1 Business overview 243 15.1.7.2 Products offered 244 15.1.7.3 Recent developments 245 15.1.7.3.1 Product launches 245 15.1.7.3.2 Deals 245 15.1.7.3.3 Expansions 246 15.1.8 OWEN MUMFORD LTD. 247 15.1.8.1 Business overview 247 15.1.8.2 Products offered 247 15.1.8.3 Recent developments 248 15.1.8.3.1 Product launches 248 15.1.8.3.2 Deals 248 15.1.9 WEIGAO MEDICAL INTERNATIONAL CO., LTD. 249 15.1.9.1 Business overview 249 15.1.9.2 Products offered 250 15.1.10 CREDENCE MEDSYSTEMS, INC. 251 15.1.10.1 Business overview 251 15.1.10.2 Products offered 251 15.1.11 NOVARTIS AG 252 15.1.11.1 Business overview 252 15.1.11.2 Products offered 253 15.1.11.3 Recent developments 254 15.1.11.3.1 Deals 254 15.1.12 STEVANATO GROUP 255 15.1.12.1 Business overview 255 15.1.12.2 Products offered 256 15.1.12.3 Recent developments 257 15.1.12.3.1 Product launches 257 15.1.12.3.2 Deals 257 15.1.12.3.3 Expansions 258 15.1.13 POLYMEDICURE 260 15.1.13.1 Business overview 260 15.1.13.2 Products offered 260   15.1.14 AMSINO INTERNATIONAL, INC. 261 15.1.14.1 Business overview 261 15.1.14.2 Products offered 261 15.1.14.3 Recent developments 262 15.1.14.3.1 Deals 262 15.1.15 SHARPS TECHNOLOGY, INC. 263 15.1.15.1 Business overview 263 15.1.15.2 Products offered 263 15.2 OTHER PLAYERS 264 15.2.1 FRESENIUS KABI USA 264 15.2.2 MEDEFIL, INC. 265 15.2.3 D.B.M. S.R.L. 266 15.2.4 TAISEI KAKO CO., LTD. 267 15.2.5 SHANDONG PROVINCE MEDICINAL GLASS CO., LTD. 268 15.2.6 SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD. 269 15.2.7 J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.) 270 15.2.8 BMI KOREA 271 15.2.9 B. BRAUN SE 272 15.2.10 AL SHIFA MEDICAL PRODUCTS CO. 273 16 RESEARCH METHODOLOGY 274 16.1 RESEARCH DATA 274 16.1.1 SECONDARY DATA 275 16.1.1.1 Key data from secondary sources 275 16.1.2 PRIMARY DATA 276 16.1.2.1 Key primary sources 276 16.1.2.2 Key objectives of primary research 276 16.1.2.3 Key data from primary sources 277 16.1.2.4 Key industry insights 278 16.2 MARKET SIZE ESTIMATION 280 16.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 280 16.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 281 16.2.3 TOP-DOWN APPROACH 282 16.3 DATA TRIANGULATION 285 16.4 MARKET SHARE ESTIMATION 286 16.5 STUDY ASSUMPTIONS 286 16.6 RESEARCH LIMITATIONS 287 16.6.1 METHODOLOGY-RELATED LIMITATIONS 287 16.7 RISK ASSESSMENT 287   17 APPENDIX 288 17.1 DISCUSSION GUIDE 288 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 293 17.3 RELATED REPORTS 295 17.4 AUTHOR DETAILS 296
圖表清單 List of Tables & Figures
TABLE 1 PREFILLED SYRINGES MARKET: INCLUSIONS & EXCLUSIONS 29 TABLE 2 STANDARD CURRENCY CONVERSION RATES 30 TABLE 3 UNMET NEEDS IN PREFILLED SYRINGES MARKET 49 TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON PREFILLED SYRINGES MARKET 52 TABLE 5 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 54 TABLE 6 ROLE OF COMPANIES IN PREFILLED SYRINGES MARKET ECOSYSTEM ANALYSIS 58 TABLE 7 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE, 2022–2025 (USD) 60 TABLE 8 AVERAGE SELLING PRICE OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025 (USD) 60 TABLE 9 AVERAGE SELLING PRICE OF SAFETY PREFILLED SYRINGES, BY REGION, 2022–2025 (USD) 61 TABLE 10 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025 (USD) 61 TABLE 11 IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND) 62 TABLE 12 EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND) 62 TABLE 13 PREFILLED SYRINGES MARKET: KEY CONFERENCES & EVENTS, JANUARY 2026–DECEMBER 2026 63 TABLE 14 CASE STUDY 1: ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS 65 TABLE 15 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION 66 TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 68 TABLE 17 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR PREFILLED SYRINGES 68 TABLE 18 LIST OF MAJOR PATENTS IN PREFILLED SYRINGES MARKET (2022−2025) 77 TABLE 19 TOP USE CASES AND MARKET POTENTIAL 79 TABLE 20 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 79 TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 25 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 26 GLOBAL STANDARDS IN PREFILLED SYRINGES MARKET 84 TABLE 27 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN PREFILLED SYRINGES MARKET 85 TABLE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREFILLED SYRINGES 86 TABLE 29 KEY BUYING CRITERIA FOR PREFILLED SYRINGES 87 TABLE 30 UNMET NEEDS FROM END-USE INDUSTRIES IN PREFILLED SYRINGES MARKET 88 TABLE 31 PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 90 TABLE 32 CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 91 TABLE 33 CONVENTIONAL PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (MILLION UNITS) 91 TABLE 34 CONVENTIONAL PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 92 TABLE 35 DISPOSABLE PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 94 TABLE 36 REUSABLE PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 96 TABLE 37 SAFETY PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (MILLION UNITS) 97 TABLE 38 SAFETY PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 98 TABLE 39 PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 100 TABLE 40 SINGLE-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 41 DUAL-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 42 CUSTOMIZED PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 43 PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 107 TABLE 44 GLASS PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 45 PLASTIC PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 46 PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 112 TABLE 47 PREFILLED SYRINGES MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 48 PREFILLED SYRINGES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 49 PREFILLED SYRINGES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 50 PREFILLED SYRINGES MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 51 PREFILLED SYRINGES MARKET FOR THROMBOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 52 PREFILLED SYRINGES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 53 PREFILLED SYRINGES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 54 PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 55 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 56 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 57 NORTH AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 58 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 129 TABLE 59 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 129 TABLE 60 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 130 TABLE 61 US: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 131 TABLE 62 US: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 131 TABLE 63 US: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 131 TABLE 64 US: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 132 TABLE 65 US: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 132 TABLE 66 CANADA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 133 TABLE 67 CANADA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 133 TABLE 68 CANADA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 134 TABLE 69 CANADA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 134 TABLE 70 CANADA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 135 TABLE 71 EUROPE: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 72 EUROPE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 73 EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 74 EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 137 TABLE 75 EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 137 TABLE 76 EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 138 TABLE 77 GERMANY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 78 GERMANY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 79 GERMANY: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 139 TABLE 80 GERMANY: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 140 TABLE 81 GERMANY: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 140 TABLE 82 UK: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 83 UK: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 84 UK: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 142 TABLE 85 UK: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 142 TABLE 86 UK: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 143 TABLE 87 FRANCE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 144 TABLE 88 FRANCE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 144 TABLE 89 FRANCE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 144 TABLE 90 FRANCE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 145 TABLE 91 FRANCE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 145 TABLE 92 SPAIN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 93 SPAIN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 94 SPAIN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 146 TABLE 95 SPAIN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 147 TABLE 96 SPAIN: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 147 TABLE 97 ITALY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148 TABLE 98 ITALY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148 TABLE 99 ITALY: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 149 TABLE 100 ITALY: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 149 TABLE 101 ITALY: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 150 TABLE 102 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 150 TABLE 103 REST OF EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 151 TABLE 104 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 151 TABLE 105 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 151 TABLE 106 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 152 TABLE 107 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 108 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 109 ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 110 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 154 TABLE 111 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 155 TABLE 112 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 155 TABLE 113 JAPAN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 114 JAPAN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 115 JAPAN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 157 TABLE 116 JAPAN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 157 TABLE 117 JAPAN: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 158 TABLE 118 CHINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 119 CHINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 120 CHINA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 159 TABLE 121 CHINA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 160 TABLE 122 CHINA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 160 TABLE 123 INDIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 124 INDIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 125 INDIA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 162 TABLE 126 INDIA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 162 TABLE 127 INDIA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 163 TABLE 128 AUSTRALIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 129 AUSTRALIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 130 AUSTRALIA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 164 TABLE 131 AUSTRALIA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 165 TABLE 132 AUSTRALIA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 165 TABLE 133 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 134 SOUTH KOREA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 135 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 167 TABLE 136 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 167 TABLE 137 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 168 TABLE 138 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 139 REST OF ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 169 TABLE 140 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 169 TABLE 141 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 169 TABLE 142 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 170 TABLE 143 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 144 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 145 LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 146 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 172 TABLE 147 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 172   TABLE 148 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173 TABLE 149 BRAZIL: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 150 BRAZIL: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 151 BRAZIL: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 174 TABLE 152 BRAZIL: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 175 TABLE 153 BRAZIL: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 175 TABLE 154 MEXICO: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 155 MEXICO: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 156 MEXICO: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 177 TABLE 157 MEXICO: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 177 TABLE 158 MEXICO: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 178 TABLE 159 ARGENTINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 160 ARGENTINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 161 ARGENTINA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 179 TABLE 162 ARGENTINA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 180 TABLE 163 ARGENTINA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180 TABLE 164 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 165 REST OF LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 166 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 182 TABLE 167 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 182 TABLE 168 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 183 TABLE 169 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 170 MIDDLE EAST & AFRICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 171 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 184 TABLE 172 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 185 TABLE 173 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 185   TABLE 174 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 175 GCC COUNTRIES: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 176 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 187 TABLE 177 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 187 TABLE 178 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 188 TABLE 179 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES IN PREFILLED SYRINGES MARKET 190 TABLE 180 PREFILLED SYRINGES MARKET: DEGREE OF COMPETITION 193 TABLE 181 PREFILLED SYRINGES MARKET: REGION FOOTPRINT 197 TABLE 182 PREFILLED SYRINGES MARKET: TYPE FOOTPRINT 198 TABLE 183 PREFILLED SYRINGES MARKET: MATERIAL FOOTPRINT 199 TABLE 184 PREFILLED SYRINGES MARKET: DESIGN FOOTPRINT 200 TABLE 185 PREFILLED SYRINGES MARKET: APPLICATION FOOTPRINT 201 TABLE 186 PREFILLED SYRINGES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 204 TABLE 187 PREFILLED SYRINGES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY TYPE AND REGION 204 TABLE 188 PREFILLED SYRINGES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–NOVEMBER 2025 207 TABLE 189 PREFILLED SYRINGES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 209 TABLE 190 PREFILLED SYRINGES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 210 TABLE 191 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 212 TABLE 192 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 213 TABLE 193 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 215 TABLE 194 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022–FEBRUARY 2026 215 TABLE 195 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022–FEBRUARY 2026 217 TABLE 196 GERRESHEIMER AG: COMPANY OVERVIEW 219 TABLE 197 GERRESHEIMER AG: PRODUCTS OFFERED 220 TABLE 198 GERRESHEIMER AG: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 221 TABLE 199 GERRESHEIMER AG: DEALS, JANUARY 2022–FEBRUARY 2026 221 TABLE 200 GERRESHEIMER AG: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 222 TABLE 201 SCHOTT: COMPANY OVERVIEW 225 TABLE 202 SCHOTT: PRODUCTS OFFERED 226 TABLE 203 SCHOTT: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 227 TABLE 204 SCHOTT: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 227 TABLE 205 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 229 TABLE 206 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 230   TABLE 207 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 231 TABLE 208 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 231 TABLE 209 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 232 TABLE 210 APTARGROUP, INC.: COMPANY OVERVIEW 235 TABLE 211 APTARGROUP, INC.: PRODUCTS OFFERED 236 TABLE 212 APTARGROUP, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 237 TABLE 213 APTARGROUP, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 237 TABLE 214 NIPRO: COMPANY OVERVIEW 239 TABLE 215 NIPRO: PRODUCTS OFFERED 240 TABLE 216 NIPRO: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 241 TABLE 217 NIPRO: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 242 TABLE 218 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY OVERVIEW 243 TABLE 219 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCTS OFFERED 244 TABLE 220 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 245 TABLE 221 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): DEALS, JANUARY 2022–FEBRUARY 2026 245 TABLE 222 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): EXPANSIONS, JANUARY 2022–FEBRUARY 2026 246 TABLE 223 OWEN MUMFORD LTD.: COMPANY OVERVIEW 247 TABLE 224 OWEN MUMFORD LTD.: PRODUCTS OFFERED 247 TABLE 225 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 248 TABLE 226 OWEN MUMFORD LTD.: DEALS, JANUARY 2022–FEBRUARY 2026 248 TABLE 227 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY OVERVIEW 249 TABLE 228 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: PRODUCTS OFFERED 250 TABLE 229 CREDENCE MEDSYSTEMS, INC.: COMPANY OVERVIEW 251 TABLE 230 CREDENCE MEDSYSTEMS, INC.: PRODUCTS OFFERED 251 TABLE 231 NOVARTIS AG: COMPANY OVERVIEW 252 TABLE 232 NOVARTIS AG: PRODUCTS OFFERED 253 TABLE 233 NOVARTIS AG: DEALS, JANUARY 2022–FEBRUARY 2026 254 TABLE 234 STEVANATO GROUP: COMPANY OVERVIEW 255 TABLE 235 STEVANATO GROUP: PRODUCTS OFFERED 256 TABLE 236 STEVANATO GROUP: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 257 TABLE 237 STEVANATO GROUP: DEALS, JANUARY 2022–FEBRUARY 2026 257 TABLE 238 STEVANATO GROUP: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 258 TABLE 239 POLYMEDICURE: COMPANY OVERVIEW 260 TABLE 240 POLYMEDICURE: PRODUCTS OFFERED 260 TABLE 241 AMSINO INTERNATIONAL, INC.: COMPANY OVERVIEW 261 TABLE 242 AMSINO INTERNATIONAL, INC.: PRODUCTS OFFERED 261   TABLE 243 AMSINO INTERNATIONAL, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 262 TABLE 244 SHARPS TECHNOLOGY, INC.: COMPANY OVERVIEW 263 TABLE 245 SHARPS TECHNOLOGY, INC.: PRODUCTS OFFERED 263 TABLE 246 FRESENIUS KABI USA: COMPANY OVERVIEW 264 TABLE 247 MEDEFIL, INC.: COMPANY OVERVIEW 265 TABLE 248 D.B.M. S.R.L.: COMPANY OVERVIEW 266 TABLE 249 TAISEI KAKO CO., LTD.: COMPANY OVERVIEW 267 TABLE 250 SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.: COMPANY OVERVIEW 268 TABLE 251 SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.: COMPANY OVERVIEW 269 TABLE 252 J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.): COMPANY OVERVIEW 270 TABLE 253 BMI KOREA: COMPANY OVERVIEW 271 TABLE 254 B. BRAUN SE: COMPANY OVERVIEW 272 TABLE 255 AL SHIFA MEDICAL PRODUCTS CO.: COMPANY OVERVIEW 273 TABLE 256 PREFILLED SYRINGES MARKET: STUDY ASUSMPTIONS 286 TABLE 257 PREFILLED SYRINGES MARKET: RISK ASSESSMENT 287 FIGURE 1 PREFILLED SYRINGES MARKET SEGMENTATION & REGIONAL SCOPE 28 FIGURE 2 PREFILLED SYRINGES MARKET: YEARS CONSIDERED 29 FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 32 FIGURE 4 PREFILELD SYRINGES MARKET SIZE, 2026–2031 (USD MILLION) 33 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PREFILLED SYRINGES MARKET 34 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF PREFILLED SYRINGES MARKET 34 FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN PREFILLED SYRINGES MARKET, BY TYPE, MATERIAL, DESIGN, AND REGION (2025) 35 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 36 FIGURE 9 INCREASING HEALTHCARE EXPENDITURE AND RISING PREVALENCE OF CHRONIC DISEASES AMONG OLDER POPULATION TO DRIVE MARKET 37 FIGURE 10 NORTH AMERICA TO DOMINATE MARKET SHARE THROUGHOUT FORECAST PERIOD 38 FIGURE 11 JAPAN AND CONVENTIONAL PREFILLED SYRINGES ACCOUNTED FOR LARGEST ASIA PACIFIC PREFILLED SYRINGES MARKET SHARE IN 2025 39 FIGURE 12 CHINA TO GROW AT HIGHEST CAGR DURING STUDY PERIOD 40 FIGURE 13 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES FROM 2026 TO 2031 41 FIGURE 14 PREFILLED SYRINGES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 15 PREFILLED SYRINGES MARKET: PORTER’S FIVE FORCES ANALYSIS 52 FIGURE 16 PREFILLED SYRINGES MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 17 PREFILLED SYRINGES MARKET: SUPPLY CHAIN ANALYSIS 59 FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN PREFILLED SYRINGES MARKET 64 FIGURE 19 INVESTMENT/VENTURE CAPITAL SCENARIO IN PREFILLED SYRINGES MARKET, 2021–2024 65 FIGURE 20 GLOBAL PATENT PUBLICATION TRENDS (JANUARY 2014–DECEMBER 2025) 75 FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PREFILLED SYRINGE PATENTS (JANUARY 2014−NOVEMBER 2025) 76 FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS PATENTS FOR PREFILLED SYRINGES (JANUARY 2014−NOVEMBER 2025) 76 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PREFILLED SYRINGES 86 FIGURE 24 KEY BUYING CRITERIA FOR PREFILLED SYRINGES, BY TYPE 87 FIGURE 25 PREFILLED SYRINGES MARKET: GEOGRAPHIC SNAPSHOT 125 FIGURE 26 NORTH AMERICA: PREFILLED SYRINGES MARKET SNAPSHOT 127 FIGURE 27 ASIA PACIFIC: PREFILLED SYRINGES MARKET SNAPSHOT 153 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN PREFILLED SYRINGES MARKET, 2020–2024 (USD MILLION) 191 FIGURE 29 PREFILLED SYRINGES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2024 192 FIGURE 30 PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 195   FIGURE 31 PREFILLED SYRINGES MARKET: COMPANY FOOTPRINT 196 FIGURE 32 PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 203 FIGURE 33 BRAND/PRODUCT COMPARATIVE ANALYSIS IN PREFILLED SYRINGES MARKET 205 FIGURE 34 EV/EBITDA OF KEY VENDORS 206 FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 206 FIGURE 36 R&D EXPENDITURE OF KEY PLAYERS AS PERCENTAGE OF TOTAL REVENUE, 2022–2024 207 FIGURE 37 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 213 FIGURE 38 GERRESHEIMER AG: COMPANY SNAPSHOT 220 FIGURE 39 SCHOTT: COMPANY SNAPSHOT 226 FIGURE 40 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT 230 FIGURE 41 APTARGROUP, INC.: COMPANY SNAPSHOT 236 FIGURE 42 NIPRO: COMPANY SNAPSHOT 240 FIGURE 43 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY SNAPSHOT 244 FIGURE 44 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY SNAPSHOT 249 FIGURE 45 NOVARTIS AG: COMPANY SNAPSHOT 253 FIGURE 46 STEVANATO GROUP: COMPANY SNAPSHOT 256 FIGURE 47 PREFILLED SYRINGES MARKET: RESEARCH DESIGN 274 FIGURE 48 PREFILLED SYRINGES MARKET: KEY DATA FROM SECONDARY SOURCES 275 FIGURE 49 PREFILLED SYRINGES MARKET: PRIMARY SOURCES 276 FIGURE 50 PREFILLED SYRINGES MARKET: KEY DATA FROM PRIMARY SOURCES 277 FIGURE 51 KEY INSIGHTS FROM INDUSTRY PLAYERS IN PREFILLED SYRINGES MARKET 278 FIGURE 52 PREFILLED SYRINGES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 278 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 279 FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 279 FIGURE 55 SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 280 FIGURE 56 REVENUE SHARE ANALYSIS ILLUSTRATION FOR BECTON, DICKINSON AND COMPANY (BD) (2025) 281 FIGURE 57 SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION (2025) 282 FIGURE 58 PREFILLED SYRINGES MARKET: TOP-DOWN APPROACH 282 FIGURE 59 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2026–2031) 284 FIGURE 60 PREFILLED SYRINGES MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 284 FIGURE 61 PREFILLED SYRINGES MARKET: DATA TRIANGULATION METHODOLOGY 285

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們